A Single and Multiple Ascending and Food Effect Study of RP7214, a DHODH Inhibitor in Healthy Adult Subjects
A Phase I, Randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Study and Food Effect Study of Oral RP7214, a DHODH Inhibitor, in Healthy Volunteers
Studieoversikt
Status
Status
Forhold
Forhold
Intervensjon / Behandling
Intervensjon / Behandling
Detaljert beskrivelse
Studietype
Studietype
Registrering (Faktiske)
Registrering
Fase
Fase
- Fase 1
Kontakter og plasseringer
Studiesteder
-
-
Nevada
-
Las Vegas, Nevada, Forente stater, 89121
- Rhizen Investigational Site
-
-
North Dakota
-
Fargo, North Dakota, Forente stater, 58104
- Rhizen Investigational Site
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Subjects willing and able to provide informed consent for the trial
- Male and non-childbearing female subjects aged 18 to 55 years
- Healthy subjects as determined by pre-study medical history, vitals, physical examination and 12-lead ECG, and clinical laboratory tests within the normal reference ranges or clinically acceptable to investigator
- Non-tobacco user/non-smokers or ex-smokers defined as someone who has stopped smoking cigarettes for at least 6 months.
- Negative screen for drugs of abuse and alcohol at screening and on admission.
- Body mass index (BMI) between 18.0 and 32.0 kg/m2 inclusive.
- A male subject who is able to procreate should agree to use one of the accepted contraceptives and agree to refrain from donating sperm for at least 3 months after dosing; and should not father a child during this period.
- Female subjects should be of non-childbearing potential.
- Willing and able to understand the nature of this study, comply with the study procedures as required by the study protocol.
Exclusion Criteria:
- Subjects with evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies) at the time of screening.
- Positive screen for hepatitis-B surface antigen (HBsAg), antibodies to the hepatitis C (HCV) or antibodies to the human immunodeficiency virus (HIV) 1 and 2.
- Subjects who received or are on Covid-19 directed prophylaxis (e.g. chloroquine or hydroxychloroquine) in last two weeks or 5x half-lives of the drug, whichever is shorter, prior to dosing.
- Subjects participating in another clinical study or use of any investigational product in last 30 days or 5x half-lives of the drug, whichever is shorter, prior to dosing.
- Pregnant or lactating females.
- Clinically significant abnormalities in physical examination and/or in laboratory tests (including hematology and chemistry panels, urinalysis) as assessed by the Investigator.
- Donation or loss of 400 mL or more of blood within eight (8) weeks prior to initial dosing, or longer if required by local regulations/procedures.
- Concomitant disease or condition that could interfere with the conduct of the study, or for which the treatment could interfere with the conduct of the study, or that would in the opinion of investigator, pose an unacceptable risk to the subject in this study.
- Inability or unwillingness to comply with study and/or follow-up procedures outlined in the protocol.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Dobbelt
Antall våpen
Våpen og intervensjoner
Deltakergruppe / ArmDeltakergruppe / Arm |
Intervensjon / BehandlingIntervensjon / Behandling |
|---|---|
|
Eksperimentell: RP7214, Single and multiple doses
In Part 1 up to 3 cohorts with single ascending doses of RP7214 at 100 mg QD, 200 mg QD and 400 mg QD. In Part 2 up to 2 cohorts with multiple ascending doses of RP7214 at 200 mg BID, 400 mg BID. |
Participants will receive single and multiple ascending doses of RP7214
|
|
Placebo komparator: Placebo, Single and multiple doses
In Part 1 up to 3 cohorts and in Part 2 up to 2 cohorts with matching placebo to RP7214 tablet
|
Participants will receive single and multiple ascending doses of matching placebo
|
Hva måler studien?
Primære resultatmål
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Assessments of Adverse Events (AEs)
Tidsramme: Day1 - day15
|
Day1 - day15
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
RP7214 Cmax
Tidsramme: 0, 0.25, 0.5, 1, 2, 4, 6, 8 and 12 hrs post dose
|
Maximum Observed Plasma Concentration
|
0, 0.25, 0.5, 1, 2, 4, 6, 8 and 12 hrs post dose
|
|
RP7214 Tmax
Tidsramme: 0, 0.25, 0.5, 1, 2, 4, 6, 8 and 12 hrs post dose
|
Time for maximum plasma concentration
|
0, 0.25, 0.5, 1, 2, 4, 6, 8 and 12 hrs post dose
|
|
RP7214 t½
Tidsramme: 0, 0.25, 0.5, 1, 2, 4, 6, 8 and 12 hrs post dose
|
Terminal half-life
|
0, 0.25, 0.5, 1, 2, 4, 6, 8 and 12 hrs post dose
|
|
RP7214 AUC0-inf
Tidsramme: 0, 0.25, 0.5, 1, 2, 4, 6, 8 and 12 hrs post dose
|
Area under the plasma concentration time curve from zero extrapolated to infinite time
|
0, 0.25, 0.5, 1, 2, 4, 6, 8 and 12 hrs post dose
|
Samarbeidspartnere og etterforskere
Sponsor
Sponsor
Publikasjoner og nyttige lenker
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Studiestart
Primær fullføring (Faktiske)
Primær fullføring
Studiet fullført (Faktiske)
Studiet fullført
Datoer for studieregistrering
Først innsendt
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Først lagt ut
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Sist oppdatering lagt ut
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Andre studie-ID-numre
Andre studie-ID-numre
- RP7214-2002
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .